Beta-secretase
BACE; β-Secretase
Beta-secretase (BACE) is a transmembrane aspartic proteinase responsible for cleaving the amyloid precursor protein (APP) to generate the soluble ectodomain sAPPbeta and its C-terminal fragment CTFbeta. BACE is a major target of Alzheimer's disease (AD) therapeutics. There are two forms of the enzyme: BACE1 and BACE2.
Deposition of amyloid-β protein (Aβ) to form neuritic plaques is the characteristic neuropathology of Alzheimer's disease (AD). Aβ is generated from APP by β- and γ-secretase cleavages. BACE1 is the β-secretase and its inhibition induces severe side effects, whereas its homolog BACE2 normally suppresses Aβ by cleaving APP/Aβ at the θ-site (Phe20) within the Aβ domain.
Beta-secretase Isoform Specific Products
All Product Categories
-
Beta-secretase Related Products (156)
Related Products (156)
-
Antibodies (1)
-
Beta-secretase Isoform Comparison
-
Eslicarbazepine Acetate-d3
0 ImagesCat. No.: HY-W744263CAS No.: 2512192-54-8Eslicarbazepine Acetate-d3 is the deuterium labeled Eslicarbazepine acetate (HY-B0703). Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.
-
TAK-070 hydrochloride hydrate
0 ImagesCat. No.: HY-114234CAS No.: 365276-12-6TAK-070 hydrochloride hydrate is a noncompetitive and orally active BACE1 inhibitor (IC50 = 3.15 μM). TAK-070 hydrochloride hydrate can be used for research of Alzheimer’s disease (AD). TAK-070 hydrochloride hydrate inhibits brain levels of soluble Aβ, and improves cognitive impairments in AD model.
-
Multitarget AD inhibitor-1
0 ImagesCat. No.: HY-136813CAS No.: 2205015-77-4Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC50s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC50hBACE-1=41.60 μM), amyloid β aggregation (IC50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research.
-
BACE1-IN-15
0 ImagesCat. No.: HY-173226BACE1-IN-15 (Compound 72) is a selective inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1) with oral activity and the ability to penetrate the blood-brain barrier. Its IC50 value is 121.65 nM (the IC50 value for BACE-2 is 480.92 nM). BACE1-IN-15 can be used in the research of the Alzheimer's disease field
-
BACE1-IN-11
0 ImagesCat. No.: HY-151348CAS No.: 1803952-77-3
-
TB-9
0 ImagesCat. No.: HY-164956CAS No.: 1415033-91-8TB-9, a Tasiamide B (HY-N15154) derivative, is a potent cathepsin D, cathepsin E, and BACE1 inhibitor with IC50s of 0.0783 nM, 0.724 nM, and 54.2 nM, respectively.
-
GRL-8234
0 ImagesCat. No.: HY-10104CAS No.: 913071-81-5GRL-8234 is a potent β-secretase (BACE1) inhibitor with blood-brain barrier penetration (Ki = 1.8 nM). GRL-8234 can rescue age-related cognitive decline in Tg2576 mice. GRL-8234 can be used in the research related to Alzheimer's disease (AD).
-
Eslicarbazepine acetate (Standard)
0 ImagesSynonyms: BIA 2-093 (Standard)Eslicarbazepine acetate (Standard) is the analytical standard of Eslicarbazepine acetate. This product is intended for research and analytical applications. Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.
-
AChE-IN-63
0 ImagesCat. No.: HY-158261CAS No.: 876685-78-8AChE-IN-63 (Compound 5AD) is a selective inhibitor of hAChE (IC50=0.103 μM). AChE-IN-63 also inhibits hBChE and hBACE-1 (IC50= 10 μM (hBChE); 1.342 μM (hBACE-1)). AChE-IN-63 inhibits Aβ aggregation, preventing the formation and deposition of Aβ1-42. AChE-IN-63 can effectively penetrate the blood-brain barrier and is orally effective. It is primarily used in Alzheimer's disease research.
-
2-Acetoxyacorenone
0 ImagesCat. No.: HY-W750970CAS No.: 185154-95-42-Acetoxyacorenone (compound 8) is a sesquiterpenoid, which can be isolated from the rhizome of Acorus tatarinowii. 2-Acetoxyacorenone has potent AChE and β-BACE1 inhibitory activity and can be used in the study of Alzheimer's disease.
-
TAK-070 Free base
0 ImagesCat. No.: HY-114234ACAS No.: 212571-56-7TAK-070 Free base is a noncompetitive and orally active BACE1 inhibitor (IC50: 3.15 μM). TAK-070 Free base can be used for research of Alzheimer’s disease (AD). TAK-070 Free base inhibits brain levels of soluble Aβ, and improves cognitive impairments in AD model.
-
BACE1-IN-12
0 ImagesCat. No.: HY-147851CAS No.: 2479315-19-8BACE1-IN-12 (compound 7g) is a potent and BBB-penetrated BACE1 inhibitor, with an IC50 of 8.9 µM. BACE1-IN-12 shows selective BuChE (butyrylcholinesterase) inhibitory activity with an IC50 of 3.2 µM. BACE1-IN-12 shows effective antioxidant effect with an IC50 of 10.2 μM (DPPH). BACE1-IN-12 might be served as a potential anti-Alzheimer agent.
-
β-Secretase Inhibitor III
0 ImagesCat. No.: HY-139720CAS No.: 2760674-85-7β-Secretase Inhibitor III is an extremely selective BACE1 inhibitor (Ki = 0.13 nM).
-
SSZ
0 ImagesSSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice.
-
OM99-2
0 ImagesCat. No.: HY-P2713CAS No.: 314266-76-7OM99-2, an eight residue peptidomimetic, tight-binding inhibitor of human brain memapsin 2 with a Ki value of 9.58 nM. OM99-2 is significantly advanced the development of BACE1 inhibitor. OM99-2 has the potential for the research of the Alzheimer's disease.
